SCHEMBL31301425

SCHEMBL31301425

O=C(O)c1ncn(-c2ccc(C(F)(F)F)cc2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
SRD5A2 P31213 1/20 0.41
MAPT P10636 4/20 0.40
NOTUM Q6P988 3/20 0.40
UBE2N P61088 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
KMT2A Q03164 1/20 0.39
ATM Q13315 1/20 0.38
OPRD1 P41143 1/20 0.38
P2RY14 Q15391 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
POLB P06746 1/20 0.38
TEAD1 P28347 1/20 0.38
TEAD4 Q15561 1/20 0.38
TEAD2 Q15562 1/20 0.38
TEAD3 Q99594 1/20 0.38
AADAT Q8N5Z0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21816146 0.82 KMT2A (0.55) TP53SMN1; SMN2NOTUMKMT2APOLB
SCHEMBL15753929 0.82 TP53 (0.61) TP53SMN1; SMN2MAPTNOTUMKMT2A
SCHEMBL18581259 0.81 MAPT (0.43) TP53SMN1; SMN2MAPTNOTUMPOLB
SCHEMBL31753907 0.80 MAPT (0.49) TP53SMN1; SMN2MAPTNOTUMKMT2A
SCHEMBL3529890 0.80 SMN1; SMN2 (0.57) TP53SMN1; SMN2MAPTPOLBCYP2C9
SCHEMBL15760357 0.79 NOTUM (0.48) TP53SMN1; SMN2MAPTNOTUMKMT2A
SCHEMBL15754705 0.79 MAPT (0.44) TP53SMN1; SMN2MAPTNOTUMPOLB
SCHEMBL31301264 0.79 MAPT (0.52) TP53SMN1; SMN2MAPTNOTUMKMT2A
SCHEMBL10360310 0.77 NOTUM (0.44) NOTUMUBE2NADORA3ATMCES2
SCHEMBL18284894 0.77 DHFR (0.42) NOTUMADORA3AADAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727549-A2 PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS University of Georgia Research Foundation, Inc. (US) 2026-04-22 EP disclosed
US-20260097046-A1 PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS UNIV GEORGIA (US) 2026-04-09 US disclosed
WO-2024258900-A2 PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2024-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260097046-A1 PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS SUB1, PFN1, HCCS TP53 4222/4885SMN1; SMN2 4264/4885SRD5A2 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.